Sign in
CompletedNo phase

The Impact of a Nutritional Supplement (Impryl®) on Male Fertility

Key facts

Who runs it
Radboud University Medical Center
Where
Netherlands21 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
1,200 people enrolled
Started
23 Apr 2018
Ended
1 Jun 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Impryl
  • Placebo
Record updated
28 August 2026

Who can take part

Age
18 years to 50 years
Sex
Men only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Couples with failure to conceive for at least 12 months and starting with EM or Couples starting with 1st/ 2nd/3rd cycle of IUI (with/without ovarian stimulation) or Couples starting with 1st/ 2nd/3rd cycle of IVF/ICSI
  • Furthermore:
  • Male with age 18-50 years
  • Female partner with age 18-43 years
  • Willing and able to give informed consent

Who cannot take part

  • Planned or performed diagnostic testicular biopsy (TESE) or percutaneous epididymal sperm aspiration (PESA)
  • Use of donor-, cryopreserved- or electro-ejaculated semen
  • Ovulation induction (OI) without IUI
  • IVF for an absolute tubal factor
  • Embryo-transfers after cryopreservation
  • Embryo-transfer after pre-implantation genetic diagnosis
  • Known genetic abnormalities related to infertility
  • Known urological abnormality such as a varicocele or bilateral cryptorchism
  • Use of other vitamin supplements

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Infertility is a worldwide problem and about 10%-15% of all couples will be affected by the inability to have children. In approximately 50% of infertile couples a male factor is involved. Male infertility is of multifactorial origin. In the past decade, the role of oxidative stress on sperm has been researched thoroughly and found to be the problem in 30% to 80% of male infertility cases.

Read full original descriptionShow less

Impryl® is a nutritional supplement mainly consisting of vitamin B, which works on the metabolic system by activating the one carbon cycle and recycling of homocysteine without the use of any direct strong antioxidants.

In this study the investigators want to determine the effectiveness of nutritional supplement Impryl® in men of infertile couples on ongoing pregnancy rate, with or without assisted reproduction technology (ART).

The 2 groups in the trial

  • ImprylExisting treatment, for comparison

    One tablet daily for 6 months

  • PlaceboPlacebo, for comparison

    One tablet daily for 6 months

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
28 August 2026